Analysts Set Immuneering Corporation (NASDAQ:IMRX) PT at $16.50

Shares of Immuneering Corporation (NASDAQ:IMRX) have received a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.50.

IMRX has been the topic of a number of research reports. Leerink Partnrs upgraded shares of Immuneering to a “strong-buy” rating in a research note on Friday, October 31st. Wall Street Zen lowered shares of Immuneering from a “hold” rating to a “sell” rating in a report on Saturday. Needham & Company LLC increased their price target on Immuneering from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Mizuho set a $12.00 price objective on Immuneering in a report on Wednesday, October 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Monday.

Immuneering Stock Down 0.4%

Shares of NASDAQ:IMRX opened at $5.65 on Friday. Immuneering has a 52-week low of $1.10 and a 52-week high of $10.08. The stock has a market cap of $364.82 million, a price-to-earnings ratio of -3.17 and a beta of 0.46. The business has a 50-day moving average price of $6.45 and a 200-day moving average price of $5.30.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, equities analysts anticipate that Immuneering will post -1.86 EPS for the current fiscal year.

Insider Transactions at Immuneering

In related news, Director Peter Feinberg acquired 7,500 shares of the stock in a transaction on Friday, October 3rd. The shares were acquired at an average price of $6.67 per share, for a total transaction of $50,025.00. Following the transaction, the director owned 156,766 shares in the company, valued at approximately $1,045,629.22. This trade represents a 5.02% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders purchased 20,800 shares of company stock valued at $143,754 over the last three months. Insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Immuneering

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after buying an additional 4,458 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Immuneering in the third quarter worth about $35,000. Future Financial Wealth Managment LLC purchased a new stake in shares of Immuneering during the 3rd quarter worth about $35,000. Dimensional Fund Advisors LP grew its position in shares of Immuneering by 46.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock valued at $137,000 after acquiring an additional 6,196 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of Immuneering in the 3rd quarter valued at about $70,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.